dc.contributor.author
Chaccour, Carlos
dc.contributor.author
Rabinovich, Regina
dc.date.issued
2017-05-10T13:26:31Z
dc.date.issued
2017-05-10T13:26:31Z
dc.date.issued
2017-04-24
dc.date.issued
2017-05-03T18:01:50Z
dc.identifier
https://hdl.handle.net/2445/110769
dc.description.abstract
The development of ivermectin as a complementary vector control
tool will require good quality evidence. This paper reviews the
different eco-epidemiological contexts in which mass drug
administration with ivermectin could be useful. Potential
scenarios and pharmacological strategies are compared in order
to help guide trial design. The rationale for a particular
timing of an ivermectin-based tool and some potentially useful
outcome measures are suggested.
dc.format
application/pdf
dc.publisher
Biomed Central
dc.relation
Reproducció del document publicat a:
http://dx.doi.org/10.1186/s12936-017-1802-3
dc.relation
Malaria Journal, 2017, vol. 16, num. 1, p. 166
dc.relation
http://dx.doi.org/10.1186/s12936-017-1802-3
dc.rights
cc by (c) Chaccour et al., 2017
dc.rights
http://creativecommons.org/licenses/by/3.0/es/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (ISGlobal)
dc.subject
Assaigs clínics
dc.subject
Clinical trials
dc.title
Ivermectin to reduce malaria transmission II. Considerations
regarding clinical development pathway
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
